2023
Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial
Rance M, Zhao Z, Zaboski B, Kichuk S, Romaker E, Koller W, Walsh C, Harris-Starling C, Wasylink S, Adams T, Gruner P, Pittenger C, Hampson M. Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial. Psychiatry Research 2023, 328: 115458. PMID: 37722238, PMCID: PMC10695074, DOI: 10.1016/j.psychres.2023.115458.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderAnterior prefrontal cortexControl groupDouble-blind clinical trialDouble-blind trialPrimary outcome measureCompulsive disorderHarm/checkingMechanism of actionYale-Brown ObsessiveSecondary outcomesSessions of neurofeedbackActive groupClinical trialsOutcome measuresPrimary symptomsSymptom ScaleObsessive-compulsive symptomsPrefrontal cortexSymptomsTraining protocolGreater reductionSignificant differencesPatientsSham feedback
2013
Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder
Kichuk SA, Torres AR, Fontenelle LF, Rosário MC, Shavitt RG, Miguel EC, Pittenger C, Bloch MH. Symptom dimensions are associated with age of onset and clinical course of obsessive–compulsive disorder. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2013, 44: 233-239. PMID: 23410525, PMCID: PMC3654083, DOI: 10.1016/j.pnpbp.2013.02.003.Peer-Reviewed Original ResearchConceptsAge of onsetClinical courseObsessive-compulsive disorderPrimary symptom dimensionsSymptom dimensionsPrimary OCD symptomsChi-square testEarly ageOCD symptom dimensionsYale-Brown ObsessiveAdult patientsComorbid ticsSignificant symptomsLarge cohortDifferent OCD symptom dimensionsHeterogeneous symptomsSymptomsCompulsive ScaleDimensional Yale-Brown ObsessiveAgeSignificant differencesOCD symptomsOnsetInconsistent results